We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson ...

J&J (NYSE:JNJ) stock surges rallying peers despite Trump's latest tariff threats on pharma as the company posts a quarterly ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.

As a baseline, the chance that JNJ will rise over any given week is 54.84%. Therefore, the statistical response to the 6-4-D ...

Raritan: Johnson & Johnson has received priority review from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) filed for TAR-200, an intravesical gemcitabine ...

J&J(JNJ) wins U.S. appeals court case protecting its Invega Sustenna patent from generic rivals Viatris (VTRS) & Teva (TEVA).

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Johnson & Johnson (NYSE: JNJ) ranks among the best forever stocks to invest in. Prior to the company’s second-quarter ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Johnson & Johnson delivered a "beat and raise" quarter. Results were bolstered by the new acquisition of Intra-Cellular, ...

Johnson & Johnson reported second-quarter results on July 16. Sales of pharmaceuticals have been muted due to a loss of ...